FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2979755727> ?p ?o ?g. }

• W2979755727 abstract "Abstract Abstract 2520 INTRODUCTION. Age, cytogenetics, FLT3 and NPM1 mutations are the most significant prognostic factors (PFs) for adult AML treated with standard regimens, but the predictive significance of FLT3 and NPM1 with contemporary treatments is unknown. We examined the clinical significance of NPM1 and FLT3 mutations in adult de novo AML pts enrolled on SWOG study S0106. METHODS. S0106 was a randomized phase III clinical trial for pts of age 18–60 with de novo non-M3 AML, evaluating the effects of adding Gemtuzumab Ozogamicin (GO) to standard induction therapy (Cytosine Arabinoside and Daunomycin, AD), and of post-consolidation GO vs. no additional therapy (ASH, 2009, Abstract 790). Samples from 198 of the 600 eligible pts were evaluated. Analyses for nucleotide insertions in exon 12 of the NPM1 gene and internal tandem duplications (ITD) within exons 14–15 of FLT3 were performed using fragment analyses in diagnostic bone marrow (BM, N=190) and peripheral blood (PB, N=8) samples. Mutant/wild-type (WT) allelic ratios (AR) were computed for all mutations. Effects of mutations and other PFs on complete response (CR), resistant disease (RD), overall survival (OS) and relapse-free survival (RFS) were analyzed by logistic and Cox regression. P-values are 2-sided. RESULTS. Patient characteristics and outcomes are shown in Table 1. In univariate analyses, NPM1-Mut pts had significantly higher CR (81% vs. 58%, P=.0018) and lower RD (13% vs. 28%, P=.028) rates, better OS (64% vs. 47%, P=.045) and RFS (54% vs. 41%, P=.50). FLT3-ITD was not associated with CR or RD, but was associated with poorer OS (hazard ratio [HR] 2.28, P=.0011) and RFS (HR 2.74, P=.0009). FLT3-ITD length (range 18–366, median 46), FLT3 AR (range 0.18–8.2, median 0.98), and NPM1 AR (range 0.2–1.0, median 0.8) were not associated with CR, RD, or OS, but RFS tended to be lower with higher ITD length (P=.076). In multivariate analyses with other PFs, neither NPM1 nor FLT3 was associated with CR or RD rates, however the combined effects of FLT3 and NPM1 identified 3 mutation risk groups for OS (P=.0044, Fig 1A) and RFS (P=.0003, Fig 1B), since NPM1 did not significantly affect outcomes within the FLT3-ITD pts. These risk groups are FLT3-WT/NPM1-Mut (Good Risk: 3-yr OS 82%, RFS 69%), FLT3-WT/NPM1-WT (Intermediate Risk: OS 49%, RFS 43%), and FLT3-ITD (Poor Risk: OS 29%, RFS 14%). The impact of adding GO to induction therapy was examined within each risk group. In each risk group, CR rates were higher in the AD+GO arm, though not significantly so. Likewise, the RD rates were lower in the AD+GO arm, but this difference was significant only in the largest group: Intermediate Risk, FLT3-WT/NPM1-WT, 17% vs. 34% (P=.026). Treatment arm did not significantly affect OS and RFS in any mutation risk group. CONCLUSION. This study confirmed prognostic effects of FLT3 and NPM1 mutations in de novo AML pts treated with AD or AD+GO. Analyses of the joint impact of NPM1 and FLT3 mutations do not rule out the possibility that they act independently. With the small numbers of pts in the “good” and “poor” risk groups, there was no clear evidence that mutation status predicts clinical benefit from adding GO to therapy. We are evaluating additional samples and will update these results as data matures. Disclosures: No relevant conflicts of interest to declare." @default.
• W2979755727 created "2019-10-18" @default.
• W2979755727 creator A5001124933 @default.
• W2979755727 creator A5002063554 @default.
• W2979755727 creator A5013596178 @default.
• W2979755727 creator A5015493242 @default.
• W2979755727 creator A5034812867 @default.
• W2979755727 creator A5037972294 @default.
• W2979755727 creator A5038741958 @default.
• W2979755727 creator A5049490094 @default.
• W2979755727 creator A5050556099 @default.
• W2979755727 creator A5056405520 @default.
• W2979755727 creator A5058189909 @default.
• W2979755727 creator A5058845981 @default.
• W2979755727 creator A5061732223 @default.
• W2979755727 creator A5071023119 @default.
• W2979755727 creator A5083798364 @default.
• W2979755727 creator A5088294011 @default.
• W2979755727 creator A5089541690 @default.
• W2979755727 date "2011-11-18" @default.
• W2979755727 modified "2023-10-01" @default.
• W2979755727 title "Prognostic Significance of FLT3 and NPM1 Mutations in Adults of Age 18–60 with De Novo Acute Myeloid Leukemia (AML) on SWOG S0106 Study: A Study by FHCRC and SWOG" @default.
• W2979755727 doi "https://doi.org/10.1182/blood.v118.21.2520.2520" @default.
• W2979755727 hasPublicationYear "2011" @default.
• W2979755727 type Work @default.
• W2979755727 sameAs 2979755727 @default.
• W2979755727 citedByCount "1" @default.
• W2979755727 countsByYear W29797557272013 @default.
• W2979755727 crossrefType "journal-article" @default.
• W2979755727 hasAuthorship W2979755727A5001124933 @default.
• W2979755727 hasAuthorship W2979755727A5002063554 @default.
• W2979755727 hasAuthorship W2979755727A5013596178 @default.
• W2979755727 hasAuthorship W2979755727A5015493242 @default.
• W2979755727 hasAuthorship W2979755727A5034812867 @default.
• W2979755727 hasAuthorship W2979755727A5037972294 @default.
• W2979755727 hasAuthorship W2979755727A5038741958 @default.
• W2979755727 hasAuthorship W2979755727A5049490094 @default.
• W2979755727 hasAuthorship W2979755727A5050556099 @default.
• W2979755727 hasAuthorship W2979755727A5056405520 @default.
• W2979755727 hasAuthorship W2979755727A5058189909 @default.
• W2979755727 hasAuthorship W2979755727A5058845981 @default.
• W2979755727 hasAuthorship W2979755727A5061732223 @default.
• W2979755727 hasAuthorship W2979755727A5071023119 @default.
• W2979755727 hasAuthorship W2979755727A5083798364 @default.
• W2979755727 hasAuthorship W2979755727A5088294011 @default.
• W2979755727 hasAuthorship W2979755727A5089541690 @default.
• W2979755727 hasConcept C104317684 @default.
• W2979755727 hasConcept C126322002 @default.
• W2979755727 hasConcept C143998085 @default.
• W2979755727 hasConcept C203014093 @default.
• W2979755727 hasConcept C2483381 @default.
• W2979755727 hasConcept C2778041864 @default.
• W2979755727 hasConcept C2778461978 @default.
• W2979755727 hasConcept C2778729363 @default.
• W2979755727 hasConcept C30481170 @default.
• W2979755727 hasConcept C53226629 @default.
• W2979755727 hasConcept C54355233 @default.
• W2979755727 hasConcept C71924100 @default.
• W2979755727 hasConcept C86803240 @default.
• W2979755727 hasConceptScore W2979755727C104317684 @default.
• W2979755727 hasConceptScore W2979755727C126322002 @default.
• W2979755727 hasConceptScore W2979755727C143998085 @default.
• W2979755727 hasConceptScore W2979755727C203014093 @default.
• W2979755727 hasConceptScore W2979755727C2483381 @default.
• W2979755727 hasConceptScore W2979755727C2778041864 @default.
• W2979755727 hasConceptScore W2979755727C2778461978 @default.
• W2979755727 hasConceptScore W2979755727C2778729363 @default.
• W2979755727 hasConceptScore W2979755727C30481170 @default.
• W2979755727 hasConceptScore W2979755727C53226629 @default.
• W2979755727 hasConceptScore W2979755727C54355233 @default.
• W2979755727 hasConceptScore W2979755727C71924100 @default.
• W2979755727 hasConceptScore W2979755727C86803240 @default.
• W2979755727 hasLocation W29797557271 @default.
• W2979755727 hasOpenAccess W2979755727 @default.
• W2979755727 hasPrimaryLocation W29797557271 @default.
• W2979755727 hasRelatedWork W1994791499 @default.
• W2979755727 hasRelatedWork W2012737918 @default.
• W2979755727 hasRelatedWork W2149244556 @default.
• W2979755727 hasRelatedWork W2332009906 @default.
• W2979755727 hasRelatedWork W2415511556 @default.
• W2979755727 hasRelatedWork W2463916652 @default.
• W2979755727 hasRelatedWork W2746335872 @default.
• W2979755727 hasRelatedWork W2906062718 @default.
• W2979755727 hasRelatedWork W2917136542 @default.
• W2979755727 hasRelatedWork W2945116220 @default.
• W2979755727 hasRelatedWork W2960812762 @default.
• W2979755727 hasRelatedWork W2961492622 @default.
• W2979755727 hasRelatedWork W2979953578 @default.
• W2979755727 hasRelatedWork W2980649184 @default.
• W2979755727 hasRelatedWork W2980659158 @default.
• W2979755727 hasRelatedWork W2981101245 @default.
• W2979755727 hasRelatedWork W2984923267 @default.
• W2979755727 hasRelatedWork W2985328773 @default.
• W2979755727 hasRelatedWork W2986573127 @default.
• W2979755727 hasRelatedWork W348959191 @default.
• W2979755727 isParatext "false" @default.
• W2979755727 isRetracted "false" @default.
• W2979755727 magId "2979755727" @default.
• W2979755727 workType "article" @default.